These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23785839)

  • 41. Megavitamin therapy for autistic children.
    Moss N; Boverman H
    Am J Psychiatry; 1978 Nov; 135(11):1425-6. PubMed ID: 707654
    [No Abstract]   [Full Text] [Related]  

  • 42. Understanding the world of children with autism.
    Beard-Pfeuffer M
    RN; 2008 Feb; 71(2):40-5; quiz 46. PubMed ID: 18386443
    [No Abstract]   [Full Text] [Related]  

  • 43. [Psychotropic drug therapy in children].
    Eggers C
    Fortschr Med; 1977 Sep; 95(33):2028-33. PubMed ID: 334649
    [No Abstract]   [Full Text] [Related]  

  • 44. [Substitutive and dietetic approaches in childhood autistic disorder: interests and limits].
    Hjiej H; Doyen C; Couprie C; Kaye K; Contejean Y
    Encephale; 2008 Oct; 34(5):496-503. PubMed ID: 19068339
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Naltrexone in autistic children: behavioral symptoms and attentional learning.
    Campbell M; Anderson LT; Small AM; Adams P; Gonzalez NM; Ernst M
    J Am Acad Child Adolesc Psychiatry; 1993 Nov; 32(6):1283-91. PubMed ID: 8282676
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neurofeedback for autistic spectrum disorder: a review of the literature.
    Coben R; Linden M; Myers TE
    Appl Psychophysiol Biofeedback; 2010 Mar; 35(1):83-105. PubMed ID: 19856096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pediatrics: megavitamin therapy for childhood psychoses and learning disabilities. Statement of the Committee on Nutrition, American Academy of Pediatrics.
    Postgrad Med; 1977 Apr; 61(4):230-3. PubMed ID: 850666
    [No Abstract]   [Full Text] [Related]  

  • 48. Omega 3 fatty acid treatment in autism.
    Meiri G; Bichovsky Y; Belmaker RH
    J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):449-51. PubMed ID: 19702497
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Guanfacine in children with autism and/or intellectual disabilities.
    Handen BL; Sahl R; Hardan AY
    J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.
    Gagliano A; Germanò E; Pustorino G; Impallomeni C; D'Arrigo C; Calamoneri F; Spina E
    J Child Adolesc Psychopharmacol; 2004; 14(1):39-47. PubMed ID: 15142390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secretin treatment for autism.
    Herlihy WC
    N Engl J Med; 2000 Apr; 342(16):1217; author reply 1218. PubMed ID: 10777378
    [No Abstract]   [Full Text] [Related]  

  • 52. Diagnostic and assessment issues related to pharmacotherapy for children and adolescents with autism.
    Campbell M; Kafantaris V; Malone RP; Kowalik SC; Locascio JJ
    Behav Modif; 1991 Jul; 15(3):326-54. PubMed ID: 1953623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secret out-of-court settlements in drug-injury cases.
    Herxheimer A
    Lancet; 1999 Feb; 353(9152):517-8. PubMed ID: 10028977
    [No Abstract]   [Full Text] [Related]  

  • 54. Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid.
    Brasić JR; Barnett JY
    Psychol Rep; 1997 Feb; 80(1):163-70. PubMed ID: 9122323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.
    Agostini C; Blau IW; Kimby E; Plesner T
    Expert Rev Clin Immunol; 2016 Sep; 12(9):921-6. PubMed ID: 27415820
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States.
    Hayashi PH
    Int J Mol Sci; 2016 Feb; 17(2):201. PubMed ID: 26861284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved social and language skills after secretin administration in patients with autistic spectrum disorders.
    Horvath K; Stefanatos G; Sokolski KN; Wachtel R; Nabors L; Tildon JT
    J Assoc Acad Minor Phys; 1998; 9(1):9-15. PubMed ID: 9585670
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration.
    Perry R; Campbell M; Adams P; Lynch N; Spencer EK; Curren EL; Overall JE
    J Am Acad Child Adolesc Psychiatry; 1989 Jan; 28(1):87-92. PubMed ID: 2914841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse effects of fenfluramine.
    Sjöholm B; Sjöholm M
    J Autism Dev Disord; 1988 Sep; 18(3):461-2. PubMed ID: 3170463
    [No Abstract]   [Full Text] [Related]  

  • 60. Commentary: The US Expert Panel on the Appropriate Use Recommendations of Aducanumab in Clinical Practice.
    Gauthier S; Rosa-Neto P
    J Prev Alzheimers Dis; 2021; 8(4):411. PubMed ID: 34585213
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.